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Abstract: Bone remodeling requires a precise balance between resorption and formation. It 
is a complex process that involves numerous factors: hormones, growth factors, vitamins, and 
cytokines, and notably osteoprotegerin (OPG) and receptor activator for nuclear factor-κB 
(RANK) ligand. The signaling pathway OPG/RANK/RANKL is key to regulation for main-
taining the balance between the activity of osteoblasts and osteoclasts in order to prevent bone 
loss and ensure a normal bone turnover. In this review, the RANK/RANKL/OPG pathway is 
described. The multiple interactions of various factors (hormones, cytokines, growth factors, 
and vitamins) with the OPG/RANK/RANKL pathway are also commented on. Finally, the 
effects of denosumab, a human monoclonal antibody that binds to RANKL and thereby inhibits 
the activation of osteoclasts, and of strontium ranelate are also described. Indeed, these two 
new drugs afford appreciable assistance in daily care practice, helping to prevent bone loss in 
patients with osteoporosis.
Keywords: osteoprotegerin, OPG, RANK, RANKL, denosumab, strontium ranelate, 
osteoporosis
Introduction
Bone remodeling is a phenomenon that first allows growth and then participates in 
the mineral homeostasis of calcium and phosphorus. Bone remodeling is a complex 
process involving numerous cells and cytokines. Recently, a major signaling path-
way has been discovered that gives a new orientation for osteoporosis treatment. 
Bone remodeling is a balance between formation and resorption through controlling 
the activity of osteoblasts and osteoclasts. In numerous bone diseases, this becomes 
unbalanced in favor of resorption, creating bone loss. Throughout this review, the 
variation of this balance according to the patient’s gender or age will be described, as 
well as the new treatment options based on the newly discovered signaling pathway 
OPG/RANK/RANKL. For this review, we conducted a PubMed search from 1995 
to 2010 using the key words “osteoprotegerin (OPG)”, “receptor activator of nuclear 
factor-κB ligand (RANKL)”, “RANK”, “aging”, “postmenopausal”, “denosumab”, 
and “strontium ranelate”.
The OPG/RANKL/RANK signaling pathway
Normal bone turnover
The cells most involved in bone turnover are osteoclasts and osteoblasts. These cells 
have counter effects on bone. The former are the resorption cells; the latter are the 
formation cells. The balance between activation and apoptosis of cells is the key to Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Dovepress
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maintaining bone mass. Formation of new bone goes through 
four steps: osteoclast activation, bone resorption, reversal 
with osteoclast inhibition and osteoblast activation, and 
finally bone formation. Therefore, everything starts by osteo-
clastogenesis. Osteoclasts are derived from the hematopoietic 
lineage and differentiate in order to degrade bone.1 The 
osteoclast precursor matures into a multinucleated cell and 
attaches itself to the bone surface, where it is attracted by 
different factors such as cytokines, hormones, and growth 
factor, and differentiates into an activated osteoclast. Once 
activated, the osteoclast starts degrading the bone surface, 
forming a lacuna. The third phase of the cycle is apoptosis 
of the osteoclast once the resorption phase is achieved, to 
allow the formation of new bone by the preosteoblasts that 
have matured in order to constitute new bone and regulate its 
mineralization. Once bone formation is achieved, osteoblasts 
apoptosis leads them either to osteocytes or to transform to 
bone surface lining cells.
Throughout aging, bone turnover unbalances in favor 
of bone resorption. Osteoporosis is a chronic bone disease 
characterized by a decreased bone mass leading to fragile 
bone and an increased risk for fractures, notably hip, verte-
bral, and forearm fractures, which are the source of a loss of 
autonomy and increased mortality in the elderly.2
Suppression or control of bone resorption is therefore a 
major therapeutic strategy to prevent or diminish bone loss. 
A critical signaling pathway with three major proteins, OPG, 
RANK, and RANKL, was discovered, thereby enlighten-
ing the cellular regulation of bone formation. OPG was 
the first protein of the pathway to be identified in 1997.3 
It was discovered in mice by sequencing random clones, 
and the full-length gene was proven to encode for a new 
tumor necrosis factor (TNF) receptor. OPG knockout mice 
revealed severe osteoporosis, whereas OPG overexpressing 
mice showed osteopetrosis.4 OPG is a member of the TNF 
receptor family but is atypical, as it is a secreted protein with 
no transmembrane domain. It contains four homologous 
domains for binding its target, RANKL. OPG is produced by 
many types of tissue, including osteoblasts, endothelial cells, 
vascular smooth muscle, and lymphoid cells, and other cell 
types, raising the question of the specificity of this protein 
in the bone mass regulation.5
It has been established that osteoclastogenesis requires 
osteoclast activation by two newly identified molecules: mac-
rophage colony-stimulating factor (M-CSF) and RANKL. 
Both of them are necessary to activate gene transcription 
allowing osteoclast differentiation.6 RANKL is another 
new member of the TNF ligand family. It is produced by 
osteoblast lineage cells and activated T-cells. M-CSF and 
RANKL have complementary activities. M-CSF increases 
the pool of osteoclast precursors, whereas RANKL binds to 
its receptor RANK expressed on osteoclast precursors and 
mature osteoclasts, enhances osteoclast differentiation, and 
promotes its activation while inhibiting its apoptosis.7,8
RANK, the receptor of RANKL, as with OPG, is a recep-
tor from the TNF family. Its essential role for the transduction 
of the RANKL signal was established in the late 1990s.9 In 
transgenic mice, knockout of either RANK or RANKL led 
to the same phenotypes, concluding that RANK and RANKL 
had very few roles apart from their interactions.4
The bone turnover pathway is a triad: RANKL binds to its 
receptor RANK in order to induce osteoclast differentiation, 
activation, and survival, whereas OPG acts as a decoy recep-
tor to RANKL and therefore inhibits osteoclast activation and 
bone resorption.10 The balance of RANKL/RANK and OPG 
is thus essential to modulate osteoclastogenesis and bone 
remodeling, and the regulators involved in this tight control 
are numerous (Figure 1).
Expression of the OPG/RANKL 
pathway
Multiple factors (hormones, cytokines, growth factors, and vita-
mins) have been described as interacting with the OPG/RANKL 
pathway. The first of these regulation factors, estrogen, is one 
of the most important known hormones to participate in bone 
turnover. The results of the different work concerning estrogen 
and its interaction with the pathway are not conflicting because 
estrogen has been shown to stimulate OPG secretion11,12 and 
also to downregulate the expression of RANKL.13
Studies on the effects of androgens have yielded conflict-
ing results on their effects on OPG. Androgens upregulated 
OPG expression in cultured mice osteoblasts,14 whereas in 
human osteoblastic cells it was shown that OPG mRNA lev-
els and protein serum levels were significantly decreased by 
5-α-dihydrotestosterone.15 RANKL expression is not affected 
by androgens in both studies.14,15 However, Proell et al in 
2009 studied orchiectomized (ORX) rats and measured free 
serum RANKL in bone marrow supernatants. In ORX rats, 
this level was threefold higher than controls; once treated 
with testosterone, RANKL returned to control levels.16 These 
results were in the same trend as in another study in which 
an inverse correlation was found between RANKL in bone 
marrow cell extracts and testosterone in ORX rats.17
Parathyroid hormone (PTH) is a proresorptive hormone as 
it has been described from the bone stimulation observed in 
patients with hyperparathyroidism. PTH treatment on cultured Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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bone marrow cells and osteoblasts in mice showed a decreased 
expression of mRNA levels of OPG and a reciprocal enhanced 
regulation of RANKL.18 The same results were found in a study 
on parathyroidectomized infusion with continuous PTH. A dose-
dependent OPG decrease with a reciprocal RANKL increase 
was shown.19 Seck et al found conflicting results while analyzing 
the expression of OPG and RANKL in human bone tissue in 
vivo in women having surgery for breast cancer. Their conclu-
sion stated that menopausal status failed to show any change in 
the expression of OPG and RANKL. However, higher levels of 
PTH were correlated to low levels of both OPG and RANKL 
mRNA transcript.20 A cohort study of women of all ages also 
showed that serum OPG negatively correlated to PTH.21
Among other regulators of the bone turnover signal-
ing pathway, numerous cytokines can promote or, on the 
contrary, decrease bone resorption. IL-1 is a proresorptive 
cytokine that upregulates RANKL and RANK and has 
yielded conflicting results on its action among OPG. Inter-
leukin 7 (IL-7),22 IL-17, and TNF-α upregulate RANKL and 
are therefore considered proresorptive agents, whereas IL-4, 
IL-13, and interferon-γ are considered antiresorptive agents 
by suppressing osteoclastogenesis.4
Growth factors are another category of the OPG/RANKL 
pathway regulators. Insulin-like growth factor (IGF)-1 is 
already known as an important growth factor for bone turn-
over because bone responsiveness to IGF-1 decreases with 
age.23 Zhao et al studied the interaction between IGF-1 and 
the OPG/RANKL pathway in healthy Chinese women. Their 
results showed a negative correlation between IGF-1 and 
OPG as well as a negative correlation with the OPG/RANKL 
ratio. However, IGF-1 positively correlated to RANKL. The 
authors’ conclusion was that the effects of IGF-1 on bone 
may be mediated by the OPG/RANKL pathway.24 The major 
limitations of this study were the use of serum levels that did 
not reflect the exact bone microenvironment RANKL levels 
and also the use of serum levels of RANKL, which are very 
hard to define given that the assays are not very sensitive.
Another study on mice23 showed that IGF-1 can stimulate 
the expression of RANKL and M-CSF in young but not old 
animals; therefore, the regulatory role of this growth factor is 
lost with aging. The authors also determined that the altera-
tion of the IGF-1 role was due to impaired receptor activation 
even though it did not account for the entire alterations of 
the IGF-1 role in bone turnover.
Preosteoclast
Cytokines
hormones
growth factor RANK
RANK
Multinucleated
osteoclast
RANKL
MCSF
Bone surface
Apoptosis
OPG
Osteoblast
lineage
Osteoblast
Bone resorption Bone formation
Figure 1 Bone turnover through the OPG/RANK/RANKL pathway. The osteoclast precursor matures into a multinucleated cell under the influence of numerous factors 
such as cytokines, hormones, and growth factors. The multinucleated cell differentiates into an activated osteoclast in the presence of MCSF and RANKL. Once activated, the 
osteoclast starts degrading the bone surface, forming a lacuna. OPG, the decoy receptor of RANKL, inhibits the continuous binding of RANKL on RANK, therefore leading 
the osteoclast to its apoptosis. Thereafter, bone formation starts with preosteoblasts that have matured into osteoblasts in order to constitute new bone.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Another growth factor was looked into. Pigment epi-
thelium-derived factor (PEDF) is a potent growth factor for 
inhibiting angiogenesis. PEDF expression in bone has been 
demonstrated, as well as its positive action on differentia-
tion of osteoblastic cells. Akiyama et al explored the link 
between bone turnover, and particularly osteoclast function, 
and PEDF.25 PEDF was shown to stimulate OPG expression 
in osteoblasts and in osteoclast precursor cells; on the other 
hand, RANKL expression was suppressed by PEDF. More-
over, PEDF was shown to inhibit osteoclast differentiation. 
The authors’ conclusion was that PEDF could be a bone 
resorption inhibitor via the upregulation of OPG.
Genetic variations and mutations have been identified in 
the OPG/RANKL pathway, and the contribution of their poly-
morphism to bone mass density (BMD) has been studied. In a 
large cohort of Chinese patients with either an extremely high 
hip BMD or an extremely low hip BMD, men with TC/CC 
genotypes of the polymorphism rs9594782 of the RANKL gene 
(TNFRSF11 A) had a significantly higher risk of extremely low 
hip BMD and lower whole-body BMD. In the same cohort, 
the A163G polymorphism of the promoter region of the OPG 
gene (TNFRSF11B) was also linked to hip BMD with a sig-
nificant association between the GG genotype and a reduced 
risk of low hip BMD.26 In a recent and large European cohort 
of men, Roshandel et al identified multiple single nucleotide 
polymorphisms in OPG, RANKL, and RANK genes associated 
with bone turnover markers and BMD.27 Genetic variations of 
this essential pathway seemed to influence bone turnover, but 
these results have still to be confirmed in other populations.
The OPG/RANK/RANKL pathway 
through aging
Although rodent studies in aged mice had shown that 
RANKL mRNA levels increased with age, OPG mRNA 
levels decreased in aged mice.28,29 Studies in humans have 
drawn the consensus that OPG increases with age in both 
men and women.21,30–32 This increase has been shown in a 
healthy aged population as well as in patients who have 
osteoporosis, but it can also be seen in other diseases, such 
as Paget’s disease of the bone and rheumatoid arthritis.4 On 
the other hand, RANKL evolution through aging has yielded 
conflicting results in several studies regarding analysis in 
women and in men of the RANKL/OPG ratio.
In women
Menopause is a crucial aging step for women, characterized 
by an estrogen deficiency leading to bone loss. In vitro stud-
ies of human osteoblast revealed that estrogen induces OPG 
production.11,33,34 Studies involving postmenopausal women 
to determine a relationship between the menopause and an 
increase in OPG put forth different conclusions. Oh et al in a 
study on healthy Korean women of all ages, found that OPG 
levels were significantly higher in postmenopausal women 
compared with premenopausal women,35 and in a large 
cohort of Austrian women aged from 19 to 96 years, OPG 
serum level was found to be negatively correlated with serum 
estradiol.21 However, it has also been shown that OPG serum 
levels were positively correlated to age but not significantly 
to the menopausal status.20,36
In women treated for menopause, Han et al showed a sig-
nificant decrease in OPG serum levels after 1 year of hormone 
replacement therapy for estrogen alone or combined with 
progesterone.37 Dehydroepiandrosterone (DHEA) is another 
hormone linked to aging, and it is known to decrease with 
aging. An in vitro study of osteoblasts cultured with DHEA 
showed that the expression of the ratio of OPG/RANKL 
mRNA was increased, leading the authors to conclude that 
DHEA could inhibit bone resorption through the OPG/
RANKL pathway.38
As the results of the relationship between OPG and meno-
pause are conflicting, the link between bone resorption mark-
ers and OPG is also conflicting. One study reported a weak 
negative correlation between OPG serum level and bone 
turnover markers in a cohort of postmenopausal women.39 
In several other cohorts, no correlation was found between 
OPG and bone resorption markers in women whatever their 
menopause status was.36,40 In contrast, a positive relation-
ship between bone turnover markers and OPG was found in 
postmenopausal women41 and in both men and women in a 
study by Indridason et al.42
Finally, the link between OPG levels, BMD, and vertebral 
fracture has also yielded conflicting results. In some studies, 
no association was found between BMD and OPG,21,39,42,43 
whereas other works demonstrated a significant inverse 
correlation between OPG and BMD,44 notably in postmeno-
pausal women without any hormone replacement therapy.45 
A positive correlation was found in two small studies of 
postmenopausal women36,46 and corroborated by a larger 
study with a follow-up of 5–10 years.47
In addition to the conflicting relationship between BMD 
and OPG, the link between the prevalence of vertebral frac-
tures and OPG serum levels has still not reached a consensus. 
Indeed, low36,41,46 and high48 OPG levels have been associated 
with vertebral fractures (Table 1).
The study of RANKL in postmenopausal women is 
even more complicated than OPG because the assay that Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Table 1 Correlation between osteoprotegerin and different markers in women
Women
Correlation
Positive Absence Negative
Aging Kudlacek et al,21 Mazziotti et al,30 
Pulsatelli et al,31 Nabipour et al,32 
Oh et al,35 Mezquita-Raya et al,36  
Khosla et al,40 Fahrleitner-Pammer et al,41 
Indridason et al,42 Liu et al,43  
Uemura et al50
estradiol Rogers et al39 Khosla et al40 Kudlacek et al21
Testosterone Khosla et al40
PTH Kudlacek et al21
BTMs Mezquita-Raya et al36 (tALP, 
TRAP), Fahrleitner-Pammer et al,41 
Indridason et al42 (OC), Liu et al43 
(urinary NTx)
Nabipour et al,32 Han et al,37  
Khosla et al40
Rogers et al,39  
Indridason et al42 (TRAP)
BMD Nabipour et al,32 Mezquita-Raya et al,36  
Chiba et al,46 Stern et al47 
(women with HRT)
Han et al,37 Rogers et al,39  
Khosla et al,40 
Indridason et al,42 Liu et al,43 
Uemura et al50
Jorgensen et al45
Abbreviations: PTH, parathyroid hormone; BTM, bone turnover markers; tALP, total alkaline phosphatase; TRAP, tartrate-resistant acid phosphatase; OC, osteocalcin; 
NTx, cross-linked N-teleopeptide of type 1 collagen; BMD, bone mass density; HRT, hormone replacement therapy.
measures RANKL serum levels is not as sensitive as the one 
used for OPG. In an animal study, serum RANKL of OPG 
knockout mice was increased by ovariectomy.49 In a few 
studies that were conducted to determine the relationship 
between aging and RANKL in postmenopausal women, 
an increase of RANKL expression was described in post-
menopausal women compared with premenopausal women 
and women using estrogen treatment.13 Conflicting results 
can again be found. Some studies did not demonstrate any 
significant difference in RANKL and menopausal status,20 
whereas some others found a decrease of RANKL in 
elderly subjects.31 Similar to OPG, the relationship between 
RANKL and BMD does not reach any consensus. Some 
works found no association;36,43 others found an inverse 
correlation.45,50
In men
All studies performed in men found that the OPG serum 
level increases with age.21,30,35,40,42,44,45,51–53 As in women, 
the correlation between OPG and sex steroids in men is 
very conflicting in the different publications. Some articles 
showed a positive correlation between free testosterone21 
and free estradiol levels and OPG.52 In contrast, some stud-
ies concluded that there was a negative correlation between 
OPG and sex steroids in men: bioavailable testosterone and 
estradiol.40 Khosla et al went further and compared the role 
of testosterone with estrogen in elderly males. The results 
showed that in hypogonadal conditions a testosterone 
supplementation treatment decreased OPG serum levels.12 
Furthermore, a negative association between OPG and PTH 
was found in men.21,52
Regarding the possible association between OPG levels 
and BMD, numerous studies observed very different results. 
Stern et al found that higher OPG levels were associated 
with higher BMD of the lumbar spine.47 In the same trend, 
another study found a borderline positive correlation between 
OPG and whole-body BMD.42 Mostly, it seems to be either 
a   negative correlation or no correlation at all that is found. 
Khosla et al and Oh et al both concluded that there was a neg-
ative correlation between OPG serum levels and BMD.40,44 
Furthermore, in a recent article, Jorgensen et al also found a 
negative association between OPG and BMD according to a 
multiple linear regression. In the same study, however, they 
did not find any correlation between OPG and bone loss after 
a 6-year follow-up.45 This absence of correlation between 
OPG serum levels and BMD was also the conclusion of 
Szulc et al in a study of men aged 19–85 years.52
When looking at the correlation between OPG and bone 
turnover markers, the results once again are very conflicting 
in men as well as in women. Some authors report a positive 
association between OPG and osteocalcin, whereas a nega-
tive correlation to bone resorption markers was observed.42 
This negative correlation with bone resorption is also noticed 
by Szulc et al.52 On the other hand, some studies showed 
a negative association to osteocaclin44 and a positive one 
between OPG and bone resorption markers40 (Table 2).Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Table  2  Correlation  between  osteoprotegerin  and  different 
markers in men
Men
Correlation
Positive Negative
Aging Kudlacek et al,21  
Mazziotti et al,30 
Pulsatelli et al,31  
Khosla et al,40 
Indridason et al,42  
Szulc et al,52 
Gannage-Yared et al53
estradiol Kudlacek et al,21  
Szulc et al52
Khosla et al,40  
Oh et al44
Testosterone Oh et al,44  
Szulc et al52
Khosla et al40
PTH Kudlacek et al,21   
Szulc et al52
BTM Khosla et al,40  
Indridason et al42 (OC)
Oh et al,44 (OC)   
Szulc et al52
BMD Indridason et al,42  
Stern et al,47 
Szulc et al52
Khosla et al,40  
Oh et al,44  
Jorgensen et al45
Abbreviations: PTH, parathyroid hormone; OC, osteocalcin; BMD, bone mass 
density.
Conflicting results are also found in men regarding the 
evolution of serum RANKL. A study that was conducted to 
determine the relationship between RANKL serum levels 
and mRNA in the bone microenvironment showed that serum 
RANKL was negatively correlated to age, whereas mRNA 
was positively correlated to the age of the subjects. Levels 
of mRNA were also positively associated to bone turnover 
markers such as osteocalcin, alkaline phosphatase, and uri-
nary deoxypyridinoline.51 When looking at the ratio RANKL/
OPG, a positive correlation was found with osteocalcin and 
estradiol levels, whereas no correlation was found with serum 
total testosterone. A trend for a significant positive correlation 
between RANKL and osteocalcin was noticed.44 In a large 
recent study, Jorgensen et al found no correlation between 
RANKL and age, and no correlation either to BMD or bone 
loss after 6 years of follow-up. Moreover, the ratio RANKL/
OPG was not correlated to bone loss.45 On the other hand, 
Stern et al in the Rancho Bernardo Study, found that the 
serum RANKL concentrations were negatively correlated 
to BMD in men.47
Limits and difficulties of the studies
As previously shown, studying OPG and RANKL in humans 
is very difficult, as it appears that the results are conflict-
ing from one publication to another. All these data have to 
be balanced by some major problems highlighted in a few 
  publications. First of all, the assays used to quantify RANKL 
serum level are not very sensitive. Indeed, in a recent study, 
only 63% of the patients had a detectable RANKL.45 Sec-
ondly, only a few studies looked at the specific bone environ-
ment regarding the expression of OPG and RANKL, mostly 
due to the difficulty of obtaining bone samples. Moreover, 
OPG and RANKL are locally active molecules, and tested 
serum is removed from the site of disease; therefore, serum 
levels might only partially reflect the actual local mechanism. 
Finally, no reference ranges have been established regarding 
OPG and RANKL serum level. They vary from one study to 
another depending on the assays used. Currently, standard 
levels for OPG and RANKL are not well established.
Preventing bone loss: treatment 
through the RANKL/OPG pathway
As shown in the rodent studies, inhibiting RANKL or RANK 
led to the concept of inhibiting their pathway as a treatment 
for osteoporosis. After testing recombinant molecules of 
either OPG or RANK and finding all exhibiting the ability 
to bind RANKL and suppress bone resorption, all these mol-
ecules were abandoned. Recently, two new drugs emerged: 
1) denosumab, directly from translation of the basic science 
of RANKL inhibition, and 2) strontium ranelate, which has 
proven effects on the RANKL/OPG pathway that emerged 
secondarily.
Denosumab
Denosumab is a human monoclonal IgG2 antibody with a 
very high affinity and specificity to RANKL. By binding to 
RANKL, as OPG does in physiological conditions, deno-
sumab blocks its binding to RANK and thereby inhibits the 
osteoclast activation. In preclinical studies, denosumab did 
not suppress bone resorption in normal mice because of its 
specificity to human RANKL. In knockin mice expressing 
chimeric (human/murine) RANKL, denosumab reduced 
bone resorption and increased cortical and cancellous 
bone mass.54
In a phase I study comparing denosumab with placebo in 
healthy postmenopausal women, a single subcutaneous injec-
tion resulted in a rapid, profound, and sustained decrease in 
bone resorption marker.55 In a phase II study, McClung et al 
compared denosumab with placebo and alendronate in 
postmenopausal women with low BMD. Denosumab was 
administrated at a dose of 6, 14, or 30 mg every 3 months or 
14, 60, 100, 210 mg every 6 months over a 12-month period. 
Results showed an increase in BMD at lumbar spine, total 
hip, and distal third of the radius. The results on BMD were Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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superior to placebo and similar to or better than for weekly 
alendronate. Again, a decrease of bone resorption marker was 
observed rapidly after denosumab injection, and the suppres-
sion of bone turnover appeared to be dose dependent.56 In a 
trial extension, these results were sustained over 24 months.57 
In phase I and II studies, the dose of 60 mg every 6 months 
seemed to be the more effective dose and was thus investi-
gated in further phase III studies.
Bone et al conducted a randomized controlled versus 
placebo study on denosumab over 2 years in postmenopausal 
osteopenic women. They observed a significant increase in 
BMD at all sites (P , 0.0001 versus placebo) after 24 months 
of treatment. At the same time, bone turnover markers (serum 
C-telopeptide [CTX1], tartrate-resistant acid phosphatase 
5b, and intact N-terminal propeptide of type 1 procollagen 
[P1 NP]) were significantly suppressed.58 A large phase III 
study, the FREEDOM trial, was conducted by Cummings et al 
in a population of 7868 postmenopausal osteoporotic women. 
They received either 60 mg of denosumab every 6 months 
or a placebo over a period of 36 months. The occurrence of 
any new vertebral, nonvertebral, and hip fractures was stud-
ied, and the authors observed that denosumab significantly 
reduced the risk of new fracture with a relative decrease 
of 68%, 40%, and 20% of vertebral, hip, and nonvertebral 
fractures, respectively.59
The unique effect of denosumab as a RANKL inhibi-
tor creates a new category of antiresorptive agent that is 
very different from bisphosphonates. Under denosumab, 
the bone turnover markers decreased quicker and in a more 
pronounced way than in the alendronate group.56 Moreover, 
once the denosumab treatment is stopped, its effects on bone 
remodeling seem to be completely reversible.60 Furthermore, 
compared with alendronate and placebo, denosumab was 
shown to be the more efficient treatment in improving bone 
mechanical properties of the femoral neck.61
A noninferiority trial was conducted in a head-to-head 
comparison of denosumab and alendronate whereby 1189 
postmenopausal women with a T-score of −2.0 or less at 
lumbar spine or total hip were included and randomized. 
They received either 60 mg subcutaneous injection of deno-
sumab every 6 months and weekly oral placebo or 70 mg 
oral alendronate and subcutaneous placebo injections every 
6 months. The change from baseline BMD (in the total hip, 
femoral neck, trochanter, lumbar spine, and one-third radius) 
at 6 and 12 months was studied, as well as the bone turnover 
markers at months 1, 3, 6, 9, and 12. At 12 months, 94% of the 
patients had completed the study. The results showed a sig-
nificant increase in BMD in the denosumab treatment group 
compared with alendronate. Increase in BMD at the total hip 
in denosumab group was 3.5% at 12 months versus 2.6% in 
the alendronate group (P , 0.0001). A significant increase 
was also observed at all measured sites. The bone turnover 
markers studied were serum CTX1 and intact N-terminal 
P1 NP. They were significantly decreased in the denosumab 
group compared with alendronate. A maximal reduction of 
P1 NP was observed at 3 months in the denosumab group 
compared with a maximal decrease at 9 months in the alen-
dronate group. Nevertheless, the median decreases in CTX1 
were similar for both treatment groups at 12 months.62
In terms of safety and tolerability, phase I and II studies 
reported similar rates of all adverse and severe adverse events 
in placebo, denosumab, and alendronate groups. However, 
a small, transient, non-dose-dependent and asymptomatic 
increase of serum PTH associated with a decrease of serum 
calcium was observed56 under denosumab. In phase III stud-
ies, the same security profile was observed with no signifi-
cant difference between placebo and denosumab. Although 
patients undergoing treatment with bisphosphonates, notably 
those receiving IV bisphosphonate therapy with chemo-, 
radiation-, or corticosteroid therapy, may develop jaw 
osteonecrosis, no such disabling adverse event was reported 
under denosumab.63
Strontium ranelate
Strontium ranelate is an oral daily drug formed of two atoms 
of stable strontium and an organic moiety (ranelic acid). 
Strontium ranelate combines the antiresorptive effect on 
bone with an additional anabolic action. In vitro studies have 
shown different effects of strontium ranelate on osteoblasts 
and osteoclasts. When studying in vitro osteoblasts, strontium 
ranelate induced a concentration-dependent increase in OPG 
mRNA expression as well as OPG secretion. On the other 
hand, RANKL mRNA and concentration were markedly 
decreased. The proposed mediator of these effects by Bren-
nan et al was the calcium-sensing receptor. Indeed, knocking 
down the receptor abolished the effects of strontium ranelate 
on OPG and RANKL.64 These findings were corroborated in 
another in vitro study in which increasing concentrations of 
strontium ranelate downregulated osteoclastic differentiation. 
Moreover, the authors showed, as in the previous publication, 
that this downregulation was mediated by calcium-sensing 
receptor and by the inhibition of the RANKL-induced nuclear 
translocation.65 Atkins et al observed the same increase of 
the OPG/RANKL by strontium ranelate in osteoblasts.66 The 
increase in BMD is not obligatorily correlated to a reduction 
of the risk of fracture, as the ‘quality’ of bone formation, and Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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notably of the network of trabeculae, is as important as its 
‘quantity’. To date, no studies have demonstrated that the in 
vitro effects of strontium ranelate on OPG/RANKL are fully 
relevant to its risk reduction of fracture.
In rodents,67 in vivo studies showed that strontium 
ranelate decreased bone resorption and increased bone forma-
tion. In a phase II study, strontium ranelate was compared 
with placebo in postmenopausal osteoporotic women with 
at least one vertebral fracture. An increase in lumbar spine 
BMD was significantly higher in the strontium ranelate group 
than in the placebo group. Moreover, urinary excretion of 
cross-linked N-telopeptide significantly decreased in the 
treatment group compared with placebo, showing a decrease 
of bone resorption. In this study, the dose of 2 g/day was 
considered to offer the best balance between efficacy and 
safety.68 In the phase III study, a dose of 2 g/day of strontium 
ranelate was compared with placebo over 3 years. After 3 
years of treatment, the increase in BMD at all measured 
sites was significant in the strontium group compared with 
the placebo group. The increase in BMD at lumbar spine 
was notably of 12.7% in the strontium group. However, it 
is well known that this BMD increase is not fully correlated 
to a risk reduction of new fracture, as strontium ranelate 
produces a BMD measurement artifact; therefore, its action 
is hardly comparable with denosumab. After 3 months of 
therapy, bone formation markers were significantly higher 
in the strontium ranelate group than in the placebo group. 
Moreover, the authors observed a risk reduction of 41% of 
new vertebral fractures during the 3-year study period in 
the treated group compared with placebo. No significant 
difference in the incidence of serious adverse events was 
observed between the groups. However, diarrhea was the 
most frequent adverse event in the strontium ranelate group, 
with a small but significantly higher rate compared with the 
placebo group (P = 0.02). This effect disappeared after the 
first 3 months of treatment.69
Conclusion
Normal bone turnover and stable bone mass depend on the 
balance between OPG and RANKL. The catabolic effects of 
RANKL are controlled by OPG, which prevents activation 
of RANKL and therefore limits the formation, activity, and 
survival of osteoclasts. The OPG/RANK/RANKL signal-
ing pathway is complex and requires numerous factors that 
interact together. Clinical trials of denosumab and strontium 
ranelate demonstrate evidence of their ability to prevent bone 
loss in patients with osteoporosis. These treatments may 
also play a significant role in future therapeutic strategies by 
preventing structural damage in rheumatoid arthritis and by 
reducing bone resorption in metastatic bone diseases, notably 
in breast and prostate cancer.
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